Characterization of degradation products of mometasone furoate

Pharmazie

Volumn 59, Issue 5, 2004, Pages 367-373

  Sahasranaman, S ^a   Issar, M ^a   Toth G ^b   Horváth, Gy ^b   Hochhaus, Guenther ^a,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

^c Department of Pharmacotherapy and Translational Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9,11 EPOXIDE MOMETASONE FUROATE; BECLOMETASONE; BETAMETHASONE VALERATE; BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; FLUNISOLIDE; GLUCOCORTICOID; HYDROCORTISONE BUTYRATE; MOMETASONE FUROATE; RBA 180; RBA 233; RBA 935; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ASTHMA; CONFERENCE PAPER; CYCLIZATION; DRUG DEGRADATION; DRUG RECEPTOR BINDING; DRUG STABILITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; SKIN DISEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BODY FLUIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HYDROGEN-ION CONCENTRATION; LUNG; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PREGNADIENEDIOLS; RATS; RECEPTORS, GLUCOCORTICOID; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2642580760     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Affrime MB, Cuss F et al. (2000) Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 40: 1227-1236.
2. Bernstein DI, Berkowitz RB et al. (1999) Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 93: 603-612.
3. Bledsoe RK, Montana VG et al. (2002) Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110: 93-105.
4. Bundgaard H, Hansen J (1980) Studies on the stability of corticosteroids VI. Kinetics of the rearrangement of betamethasone-17-valerate to the 21-valerate ester in aqueous solution. Int J Pharm 7: 197-203.
5. Dahlberg E, Thalen A et al. (1984) Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids. Mol Pharmacol 25: 70-78.
6. Foe K, Brown KF et al. (1998) Decomposition of beclomethasone propionate esters in human plasma. Biopharm Drug Dispos 19: 1-8.
7. Isogai M, Shimizu H et al. (1993) Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol 44: 141-145.
8. Kalkwarf DR (1983) Dissolution rates of uranium compounds in simulated lung fluid. Sci Total Environ 28: 405-414.
9. Krishnaswami S, Mollmann H et al. (2000) A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. J Pharm Biomed Anal 22: 123-129.
10. Mori M, Pimpinelli N et al. (1994) Topical corticosteroids and unwanted local effects. Improving the benefit/risk ratio. Drug Safety 10: 406-412.
11. Nayak AS, Banov C et al. (2000) Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 84: 417-424.
12. Necela BM, Cidlowski JA (2003) Crystallization of the human glucocorticoid receptor ligand binding domain: a step towards selective glucocorticoids. Trends Pharmacol Sci 24: 58-61.
13. Onrust SV, Lamb HM (1998) Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 56: 725-745.
14. Prakash A, Benfield P (1998) Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 55: 145-163.
15. Sharpe M, Jarvis B (2001) Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 61: 1325-1350.
16. Teng XW, Cutler DC et al. (2003) Degradation kinetics of mometasone furoate in aqueous systems. Int J Pharm 259: 129-141.
17. Teng XW, Foe K et al. (2001) High-performance liquid chromatographic analysis of mometasone furoate and its degradation products: application to in vitro degradation studies. J Pharm Biomed Anal 26: 313-319.
18. Würthwein G, Rohdewald P (1992) Lipophilicity and receptor affinity of glucocorticoids. Pharm Ztg Wissensch 5/137: 161-167.
19. Yip YW, Li Wan Po A Rodewald P (1983) Kinetics of decomposition and formulation of hydrocortisone butyrate in semiaqueous and gel systems. J Pharm Sci 72: 776-781.